CNS Neurology logo

eLearning Seminar
Regulatory and Nonclinical Considerations for the Development of CNS/Neurology Therapeutics

To further its mission to educate, lead, and serve, the American College of Toxicology is proud to offer a new eLearning Seminar focused on development of CNS/Neurology Therapeutics. These four modules are intended to provide insight into the development of therapeutics for CNS/Neurology diseases, focusing on the regulatory and nonclinical considerations for safety assessment of therapies encompassing standard and novel modalities, including small molecules, biologics, anti-sense oligonucleotides (ASOs)/miRNA, and advanced cell and gene therapies.

These modules feature presentations by recognized experts in the field. Modules are available for purchase as a set. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is 90 minutes or fewer in duration with the exception of module 4 which will extend up to 120 minutes.

Disclaimer:

This seminar reflects the views of the speaker and should not be construed to represent the views or policies of the American College of Toxicology. Examples presented in this seminar may have required unique strategies that do not necessarily apply to other modalities or situations. Regulatory guidelines and best practices are constantly evolving, and the viewer is encouraged to independently confirm their understanding with what was presented in this seminar.  

Module 1: On Demand
Regulatory Considerations for the Development of CNS/Neurology Therapeutics

Advanced
Emerging
Mondona McCann, PhD, US FDA
Module 1 Abstract


Module 2: On Demand
Nonclinical Development of AAV-Based Gene Therapy for Spinal Muscular Atrophy

Advanced
Emerging
Francis Tukov, PhD, DVM, DABT, Novartis Pharmaceuticals Corporation
Module 2 Abstract


Module 3: On Demand
Nonclinical Development of Antisense Oligonucleotide for Spinal Muscular Atrophy

Advanced
Emerging
Scott Henry, PhD, Ionis Pharmaceuticals, Inc.
Module 3 Abstract


Module 4: On Demand
Part 1: Development of Biologics for CNS Diseases

Advanced
Emerging
Lorrene Buckley, PhD, DABT, ATS, Eli Lilly and Company
Module 4 Abstract

Part 2: The Art of CNS Drug Development: Delivery Strategies, Neurotoxicology Endpoints, and Regulatory Considerations
Advanced
Emerging
Simon Authier, DVM, MSc, MBA, PhD, DSP, Charles River Laboratories
Module 4 Abstract

The Regulatory and Nonclinical Considerations for the Development of CNS/Neurology Therapeutics eLearning seminar content will only be available until December 31, 2026.

As part of your registration, you will have unlimited access to either the individual module or set of modules recordings for 30 days. The 30-day access will begin when you access each individual module link. Certificates will be provided for each module. If you have any additional questions, please contact ACT Headquarters.

Registration Fees:

Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancelations or refunds will be allotted after payment is processed.

  Set/Modules 1–4
ACT Student/Postdoctoral Researcher Members $125
ACT Members $225
Nonmembers $350

*Fees are accessed according to the membership status at the time of purchase (there are no exceptions and there are no refunds.)

TOP